The article examines whether Yatharth Hospital’s growing focus on oncology can become a meaningful earnings driver as the company tries to increase revenue per occupied bed. Oncology already contributes close to 10% of group revenue despite only one LINAC being operational, while two more are planned at Faridabad Sector-20 and New Delhi.
It also examines whether this expansion, along with a stronger cash and private-insurance mix and higher-value treatments, can push the company’s average revenue per occupied bed above the current Rs.34,758 and support stronger profitability as newer hospitals scale up.
With a market capitalization of around Rs.10,883.71 crore, Yatharth Hospital & Trauma Care Services Ltd shares were trading at Rs.1,129.55 per share, up by 0.56% from the previous close. The stock has also attracted investor attention as ace investors Mukul Agrawal and Vijay Kedia hold stakes in the company. They hold 1.14% and 1% stake respectively in the company.
Q1 FY27 Revenue Growth Is Strong, but PAT Growth Is Slower
Yatharth reported Q1 FY27 revenue of Rs.392.7 crore, up 51.5% YoY from Rs.259.2 crore and 14.9% QoQ from Rs.341.6 crore. EBITDA increased 39% YoY and 14.7% QoQ to Rs.91.7 crore.
PAT stood at Rs.45.4 crore, up 8% YoY from Rs.42 crore and only 1.6% QoQ from Rs.44.7 crore. EBITDA margin stood at 23.3%, versus 25.4% a year ago and 23.4% in Q4 FY26, while adjusted EBITDA margin excluding ramp-up losses at Model Town and Faridabad Sector-20 was 28.1%.
This difference matters. Revenue is benefiting from new capacity, but depreciation and finance costs have risen after investments in hospitals and oncology equipment, so the full operating benefit has not yet flowed into PAT.
Oncology Is Already 10% of Revenue With One LINAC
The more interesting growth lever is oncology. Management said oncology already contributes close to 10% of group revenue even though only one LINAC machine is currently operational at Noida Extension.
Also read: Adroit Industries IPO Opens Tomorrow; 7 Key Points Investors Need to Know Before Applying
Yatharth is adding another LINAC at Faridabad Sector-20 and plans to follow this with New Delhi. Its presentation shows one hospital currently equipped with LINAC infrastructure and two more in the pipeline.
This matters because oncology is part of the company’s move towards higher-value specialities. If additional oncology capacity attracts more complex cases, the benefit can come through both higher revenue and a stronger case mix.
ARPOB Is Already Close to Rs.35,000
The headline threshold is already close. Group ARPOB reached Rs.34,758 in Q1 FY27, compared with Rs.32,581 in Q1 FY26 and Rs.33,283 in Q4 FY26, implying growth of about 6.7% YoY and 4.4% QoQ.
Several hospitals are already above the group average. New Delhi has reached around Rs.50,000 ARPOB, Greater Noida around Rs.43,000 and Faridabad Sector-20 nearly Rs.40,000, while Noida and Greater Faridabad are around Rs.35,000.
Therefore, crossing Rs.35,000 at the group level does not require a dramatic change. Management has indicated around 9-10% ARPOB growth for FY27, which, if achieved, would place the group comfortably above the current level.
Payer Mix Could Strengthen the Oncology Effect
Oncology expansion is not happening alone. New Delhi and Faridabad Sector-20 are already close to 90% cash and private-insurance business, while government business at these newer hospitals is below 10%.
Management has deliberately restricted government business in some facilities and is also working on international patient flows. The logic is that a better payer mix, combined with oncology and other advanced procedures, can lift ARPOB without relying only on higher occupancy.
This also explains why occupancy should not be read in isolation. New census beds are being commissioned gradually, which can temporarily affect reported occupancy even as patient volumes and revenue rise; Delhi’s census-bed base, for instance, increased from 100 to 150, while Faridabad increased from 100 to 200.
Can Oncology Push Earnings Per Bed Above Rs.35,000?
On the operating metric, the answer appears achievable. Yatharth is already at Rs.34,758 ARPOB, oncology contributes close to 10% of revenue, two additional LINAC installations are planned and some hospitals already generate Rs.40,000-Rs.50,000 per occupied bed.
However, Rs.35,000 is technically a revenue-per-occupied-bed measure rather than profit per bed. Whether higher oncology revenue translates into stronger earnings will depend on utilisation, doctor costs, ramp-up losses and how quickly newer hospitals reach mature margins.
Faridabad Sector-20 reaching EBITDA breakeven in nine months is encouraging, and management expects hospitals after breakeven to move towards 15-20% EBITDA margins within 15-18 months. Still, continuous capacity additions mean consolidated margins may not immediately return to 28%.
The Bottom Line
Oncology can be an important contributor to Yatharth’s move, but it is not the only driver. The stronger case rests on oncology expansion working with premium hospitals, higher cash and insurance mix, rising utilisation and scaling of newer facilities.
For investors, the key evidence is whether ARPOB moves above Rs.35,000 while oncology’s contribution rises and the gap between strong revenue growth and slower PAT growth starts narrowing. If that happens, the speciality strategy would be translating from higher revenue per bed into stronger earnings quality.